Chennai, India | February 11, 2014


Financial highlights for Quarter ended December 31, 2013 (Q1 FY14)
  • Revenue ofRs 371.60 crore (US$ 60.1 million) in the quarter ended December 31,2013 (Q1 FY14) as against Rs 313.53 crore (US$ 50.7 million) in the quarter ended December 31, 2012 (Q3 FY13)
  • EBITDA of Rs.109.49 crore (US$ 17.7 million) in the quarter ended December 31,2013 versus Rs 23.35 crore (US$ 3.8 million) in the quarter ended December 31, 2012
  • Loss before Tax of Rs. 53.90 crore (US$ 8.7 million) in the quarter ended December 31, 2013 compared to a loss before tax of Rs. 91.99 crore (US$ 14.9 million) during the quarter ended December 31, 2012
  • At the net level, the company registered a loss of Rs 53.90 crore (US$ 8.7million) in the quarter ended December 31, 2013 compared to a loss of Rs. 72.36 crore (US$ 11.7 million) during the quarter ended December 31, 2012.
Financial year revision

The company had extended its last financial year (FY 2012-13) by 6 months to September 30, 2013. Consequently, the current financial year (FY 2013-14) would consist of only of 6 months, i.e., from October 2013 to March 31, 2014.

* 1 US$ = Rs 61.81

From the Chairman & Managing Director

"Though the Company continues to face tight working capital situation, the approval for the Corporate Debt Restructuring Package (CDR), expected before end of February 2014 would facilitate completion of Penicillin and Carbapenem Business Transfer to Hospira and also bring in working capital availability from deal proceeds besides deleveraging debt profile. With this the Company would be on a better platform to achieve improved performance in the quarters to come" said Mr. K. Raghavendra Rao, Chairman & Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.

distributed by